<SEC-DOCUMENT>0001171843-17-003905.txt : 20170630
<SEC-HEADER>0001171843-17-003905.hdr.sgml : 20170630
<ACCEPTANCE-DATETIME>20170630150406
ACCESSION NUMBER:		0001171843-17-003905
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20170629
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170630
DATE AS OF CHANGE:		20170630

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Capstone Therapeutics Corp.
		CENTRAL INDEX KEY:			0000887151
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				860585310
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21214
		FILM NUMBER:		17941749

	BUSINESS ADDRESS:	
		STREET 1:		1275 WEST WASHINGTON STREET
		STREET 2:		SUITE 101
		CITY:			TEMPE
		STATE:			AZ
		ZIP:			85281
		BUSINESS PHONE:		6022865520

	MAIL ADDRESS:	
		STREET 1:		1275 WEST WASHINGTON STREET
		STREET 2:		SUITE 101
		CITY:			TEMPE
		STATE:			AZ
		ZIP:			85281

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHOLOGIC CORP
		DATE OF NAME CHANGE:	19940211
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k_063017.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">UNITED STATES</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549<BR>
______________________</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">FORM 8-K<BR>
CURRENT REPORT</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Pursuant to Section 13 or 15(d)<BR>
of the Securities Exchange Act of 1934</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">_______________________</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Date of Report: June 29, 2017 (Date of earliest event reported)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><BR>
CAPSTONE THERAPEUTICS CORP.</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B><BR>
(Exact name of registrant as specified in its charter)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border-bottom: Black 1pt solid; text-align: center; text-indent: 0in">Delaware</TD>
    <TD STYLE="width: 2%; text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 34%; border-bottom: Black 1pt solid; text-align: center; text-indent: 0in">000-21214</TD>
    <TD STYLE="width: 2%; text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 31%; border-bottom: Black 1pt solid; text-align: center; text-indent: 0in">86-0585310</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0in">(State or other jurisdiction of incorporation)</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">(Commission File Number)</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">(I.R.S. Employer</P>
        <P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center; text-indent: 0in; width: 49%">1275 West Washington Street, Suite 104, Tempe, Arizona</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; text-indent: 0in; width: 49%">85281</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: center">(Address of principal executive offices) </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Zip Code)</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0pt 0"><BR> </P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Registrant&rsquo;s telephone number, including area code:<BR>
(602) 286-5520</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 55pt; text-align: right">[ &nbsp;]</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 55pt; text-align: right">[ &nbsp;]</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 55pt; text-align: right">[ &nbsp;]</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 55pt; text-align: right">[ &nbsp;]</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (17 CFR &sect;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2). Emerging growth
company [&nbsp; ]</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. [ &nbsp;]</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: -0.75pt; margin: 0pt 0"><B>Section 2 &ndash; Financial Information</B></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: -0.75pt; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD NOWRAP STYLE="width: 55pt; text-align: left"><B>Item 2.03.</B></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><B> Creation of a Direct Financial Obligation or an Obligation under an Off-Balance
Sheet Arrangement of a Registrant.</B></TD>
</TR></TABLE>



<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">On December 11, 2015, Capstone Therapeutics Corp. (&quot;we,&quot; our,&quot; &quot;us&quot;
or the &ldquo;Company&rdquo;) entered into a Securities Purchase Agreement (the &ldquo;Agreement&rdquo;) with Biotechnology Value
Fund affiliated entities Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS,
L.P., Investment 10, LLC, and MSI BVF SPV, LLC (the &quot;Lenders&rdquo;) (Included as Exhibit 10.1 to the Company&rsquo;s Current
Report on Form 8-K filed with the Securities and Exchange Commission on December 15, 2015). The Lenders currently own in the aggregate
approximately 19% of our outstanding Common Stock, par value $.0005 per share (&quot;Common Stock&quot;).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">P<FONT STYLE="font-size: 10pt">ursuant to the Agreement, the Lenders funded an aggregate
of $1,000,000 of loans to us, evidenced by Convertible Promissory Notes (the &ldquo;Notes&rdquo;) dated December 11, 2015 and due
April 30, 2017. On April 28, 2017 the Lenders entered into a Letter Agreement extending the maturity of the Notes to June 15, 2017
(Included as Exhibit 10.1 to the Company&rsquo;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission
on May 4, 2017). On June 12, 2017, the Lenders entered into the 2<SUP>nd</SUP> Letter Agreement to extend the maturity of the Notes
to June 30, 2017 (Included as Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange
Commission on June 15, 2017). On June 29, 2017 the Lenders entered into the 3rd Letter Agreement to extend the maturity of the
Notes to July 14, 2017. The Notes bear interest at 5% per annum and are secured by a security interest in all of our assets. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">A copy of the 3rd Letter Agreement is filed with this report as Exhibit 10.1 and is incorporated
into this Item 2.03 by this reference.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: -0.75pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: -0.75pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: -0.75pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: -0.75pt; margin: 0pt 0"><B>Section 9 &ndash; Financial Statements and
Exhibits</B></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: -0.75pt; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD NOWRAP STYLE="width: 55pt; text-align: left">Item 9.01</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"> Financial Statements and Exhibits.</TD>
</TR></TABLE>



<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: left"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: left"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               <TR STYLE="vertical-align: top">
<TD>(d)</TD><TD>Exhibits</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><B><U>Exhibit No.</U></B></TD><TD><B><U>Description</U></B></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 1in">10.1</TD><TD>3rd Letter Agreement dated June 29, 2017 to the Securities Purchase Agreement dated December 11, 2015, by and among Capstone
Therapeutics, Corp. and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS,
L.P., Investment 10, LLC, and MSI BVF SPV, LLC.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -1in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0"><BR>
</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">SIGNATURES</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0; width: 33%">Dated: June 30, 2017</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 33%">CAPSTONE THERAPEUTICS CORP.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 20pt"><U>/s/ John M. Holliman, III</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 20pt">John M. Holliman, III</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 20pt">Executive Chairman and CEO</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-indent: -0.5in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: -0.5in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: -0.5in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font-size: 10pt; text-indent: -0.5in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Exhibit Index</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD><B><U>Exhibit No.</U></B></TD><TD><B><U>Description</U></B></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 1in">10.1</TD><TD>3rd Letter Agreement dated June 29, 2017 to the Securities Purchase Agreement dated December 11, 2015, by and among Capstone
Therapeutics, Corp. and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS,
L.P., Investment 10, LLC, and MSI BVF SPV, LLC.</TD></TR></TABLE>
<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exh_101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0; text-indent: 5.25in"><B>Exhibit 10.1</B></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0; text-indent: 5.25in"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>3rd Letter Agreement </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="color: #262323">This Letter Agreement is by and between Capstone Therapeutics
Corp., a Delaware corporation, having its principal business at 1275 West Washington Street, Suite 104, Tempe, AZ 85281 </FONT>(&quot;Capstone&quot;)<FONT STYLE="color: #262323">,
its joint venture, LipimetiX Development, Inc., a Delaware corporation, having its principal business at 5 Commonwealth Road, Suite
2a, Natick, MA 01760 (</FONT>&quot;LipimetiX&quot;<FONT STYLE="color: #262323">), and </FONT>Biotechnology Value Fund, L.P., Biotechnology
Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P., Investment 10, LLC, and MSI BVF SPV, LLC. (the &quot;<U>BVF Parties</U>&quot;).</P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Re: Securities Purchase Agreement dated as of December 11, 2015, the
Letter Agreement dated April 28, 2017, and the 2<SUP>nd</SUP> Letter Agreement dated June 12, 2017, by and among Capstone Therapeutics
Corp. and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P., Investment
10, LLC, and MSI BVF SPV, LLC.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Please refer to the above Securities Purchase Agreement (the &quot;<U>Agreement</U>&quot;).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Capitalized terms used in this letter agreement without definition
shall have the meanings set forth herein.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">By execution of this letter agreement below, each of the undersigned
BVF Parties agrees as follows:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Extension of Maturity
Date</U>. The Maturity Date shall be extended from June 30, 2017 by 14 days to July 14, 2017.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">Except as expressly modified hereby, the Agreement shall remain in full force
and effect.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><U>This letter agreement shall be governed by and construed under
the laws of the State of California as applied to agreements among California residents, made and to be performed entirely within
the State of California. </U>This letter agreement may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. Any signature page delivered electronically or
by facsimile (including without limitation transmission by .pdf) shall be binding to the same extent as an original signature page.
Any party who delivers such a signature page agrees to later deliver an original counterpart to the other party if so requested.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Please confirm your agreement hereto by executing the acknowledgement
and agreement below and returning it to the undersigned via email or fax.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Kind regards,</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD NOWRAP STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; width: 33%"><FONT STYLE="text-transform: uppercase"><B>Capstone Therapeutics Corp.</B></FONT></TD>
    <TD STYLE="width: 25%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 42%"><FONT STYLE="text-transform: uppercase"><B>LipimetiX Development, InC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">By: <U>/s/ John M. Holliman, III</U></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Name: John M. Holliman</TD>
    <TD>&nbsp;</TD>
    <TD>By: <U>/s/ John M. Holliman, III</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Title: Executive Chairman</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 20pt">John M. Holliman</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 20pt">Executive Chairman</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">ACKNOWLEDGED AND AGREED, as of this 29th day of June 2017:</P>

<P STYLE="font-size: 10pt; text-indent: 3in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0"><B>Biotechnology Value Fund, L.P.</B></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0"><B>By: BVF, Inc., General Partner</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0">By: <U>/s/ Mark Lampert</U></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0">Mark Lampert</P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0">Title: President</P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0"><B>Biotechnology Value Fund II, L.P.</B></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0"><B>By: BVF, Inc., General Partner</B></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0">By: <U>/s/ Mark Lampert</U></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0"><U></U>Name: Mark Lampert</P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0">Title: President</P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0"><B>Investment 10, LLC</B></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0"><B>By: BVF, Inc., attorney-in-fact</B></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0">By: <U>/s/ Mark Lampert</U></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0"><U></U>Name: Mark Lampert</P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0">Title: President</P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0"><B>MSI BVF SPV, LLC</B></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0"><B>By: BVF, Inc., attorney-in-fact</B></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0">By: <U>/s/ Mark Lampert</U></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0"><U></U>Name: Mark Lampert</P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0">Title: President</P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0"><B>Biotechnology Value Trading</B></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0"><B>Fund OS, L.P.</B></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0"><B>By: BVF Partners OS, Ltd.,</B></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0"><B>General Partner</B></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0"><B>By: BVF Partners L.P.,</B></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0"><B>Managing Member</B></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0"><B>By: BVF, Inc., General Partner</B></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0">By: <U>/s/ Mark Lampert</U></P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0"><U></U>Name: Mark Lampert</P>

<P STYLE="font-size: 10pt; text-indent: 360pt; margin: 0pt 0">Title: President</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
